Altogether, the findings obtained to date in preclinical and clinical models suggest that ERβ manipulation by ligands or new drugs might be useful in PC therapeutic approaches, particularly during the initial stages of PC. This evidence concerns the gene ESR2 and pachyonychia congenita.